Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

ClinicalTrials.gov ID: NCT02467270

Public ClinicalTrials.gov record NCT02467270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.

Study identification

NCT ID: NCT02467270
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Takeda; Industry
Enrollment: 283 participants

Conditions and interventions

Conditions

Myeloid Leukemia, Chronic, Chronic Phase

Interventions

Ponatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 13, 2015 (Actual)
Primary completion: Apr 29, 2020 (Actual)
Completion: Apr 23, 2025 (Actual)
Last update posted: Mar 17, 2026

2015 – 2025

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 15

Facility	City	State	ZIP	Site status
Emory University Winship Cancer Institute	Atlanta	Georgia	30322	—
Indiana Blood & Marrow Transplantation	Indianapolis	Indiana	46237	—
University of Maryland Medical Center	Baltimore	Maryland	21201	—
Michigan Medicine	Ann Arbor	Michigan	48109	—
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	—
University of Minnesota Medical School	Minneapolis	Minnesota	55455	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Memorial Sloan-Kettering Cancer Center - New York	New York	New York	10065	—
NewYork-Presbyterian Weill Cornell Medical Center	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27710	—
Cleveland Clinic Taussig Cancer Institute Main Campus	Cleveland	Ohio	44195	—
Oregon Health and Science University	Portland	Oregon	97239	—
Abramson Cancer Center	Philadelphia	Pennsylvania	19104	—
MD Anderson Cancer Center	Houston	Texas	77030	—
University of Utah Huntsman Cancer Institute	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02467270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02467270 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →